Cognetivity Neurosciences Stock Performance
| CGNSF Stock | USD 0 0 25.00% |
Cognetivity Neurosciences holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.2, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cognetivity Neurosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cognetivity Neurosciences is expected to be smaller as well. Use Cognetivity Neurosciences information ratio, downside variance, day typical price, as well as the relationship between the treynor ratio and kurtosis , to analyze future returns on Cognetivity Neurosciences.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cognetivity Neurosciences are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, Cognetivity Neurosciences reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.4 M | |
| Total Cashflows From Investing Activities | -100 K |
Cognetivity |
Cognetivity Neurosciences Relative Risk vs. Return Landscape
If you would invest 0.40 in Cognetivity Neurosciences on August 27, 2024 and sell it today you would lose (0.10) from holding Cognetivity Neurosciences or give up 25.0% of portfolio value over 90 days. Cognetivity Neurosciences is currently producing 4.5334% returns and takes up 34.5717% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Cognetivity, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cognetivity Neurosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cognetivity Neurosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Cognetivity Neurosciences, and traders can use it to determine the average amount a Cognetivity Neurosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1311
| Best Portfolio | Best Equity | CGNSF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 34.57 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.53 actual daily | 90 90% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Cognetivity Neurosciences is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cognetivity Neurosciences by adding it to a well-diversified portfolio.
Cognetivity Neurosciences Fundamentals Growth
Cognetivity Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cognetivity Neurosciences, and Cognetivity Neurosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cognetivity Pink Sheet performance.
| Return On Equity | -6.43 | |||
| Return On Asset | -2.04 | |||
| Current Valuation | 15.68 M | |||
| Shares Outstanding | 85.05 M | |||
| Price To Book | 189.01 X | |||
| EBITDA | (13.04 M) | |||
| Cash And Equivalents | 61.23 K | |||
| Total Debt | 1.37 M | |||
| Debt To Equity | 3.60 % | |||
| Book Value Per Share | (0.09) X | |||
| Cash Flow From Operations | (3.21 M) | |||
| Earnings Per Share | (0.14) X | |||
| Total Asset | 2 M | |||
About Cognetivity Neurosciences Performance
By analyzing Cognetivity Neurosciences' fundamental ratios, stakeholders can gain valuable insights into Cognetivity Neurosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cognetivity Neurosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cognetivity Neurosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cognetivity Neurosciences Ltd. operates as a healthcare company. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada. Cognetivity Neurosciences operates under Health Information Services classification in the United States and is traded on OTC Exchange.Things to note about Cognetivity Neurosciences performance evaluation
Checking the ongoing alerts about Cognetivity Neurosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cognetivity Neurosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cognetivity Neurosciences is way too risky over 90 days horizon | |
| Cognetivity Neurosciences has some characteristics of a very speculative penny stock | |
| Cognetivity Neurosciences appears to be risky and price may revert if volatility continues | |
| Cognetivity Neurosciences has high likelihood to experience some financial distress in the next 2 years | |
| Cognetivity Neurosciences has accumulated 1.37 M in total debt with debt to equity ratio (D/E) of 3.61, implying the company greatly relies on financing operations through barrowing. Cognetivity Neurosciences has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Cognetivity Neurosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Cognetivity Neurosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cognetivity Neurosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cognetivity to invest in growth at high rates of return. When we think about Cognetivity Neurosciences' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (13.13 M) with loss before overhead, payroll, taxes, and interest of (4.02 M). | |
| Cognetivity Neurosciences has accumulated about 61.23 K in cash with (3.21 M) of positive cash flow from operations. | |
| Roughly 15.0% of Cognetivity Neurosciences shares are held by company insiders |
- Analyzing Cognetivity Neurosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cognetivity Neurosciences' stock is overvalued or undervalued compared to its peers.
- Examining Cognetivity Neurosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cognetivity Neurosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cognetivity Neurosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cognetivity Neurosciences' pink sheet. These opinions can provide insight into Cognetivity Neurosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cognetivity Pink Sheet analysis
When running Cognetivity Neurosciences' price analysis, check to measure Cognetivity Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognetivity Neurosciences is operating at the current time. Most of Cognetivity Neurosciences' value examination focuses on studying past and present price action to predict the probability of Cognetivity Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognetivity Neurosciences' price. Additionally, you may evaluate how the addition of Cognetivity Neurosciences to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |